Absci cuts workforce 15% (30 employees), lowers 2023 cash burn guidance to ~$80M

Absci Corp

Global workforce reduced ~15% (30 employees) to focus on internal drug pipeline and AI platform.
2023 gross cash use expected ~$80M, down from prior ~$90M; cash runway extended to late 2025.
No impact expected on ability to execute current/projected partner programs.
Organizational realignment driven by AI and wet lab integration efficiencies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.